Laura K. Shawver

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

B Millauer, Laura K. Shawver, Karl H. Plate et al. · Nature · 1994 · 1.2K citations

Tumor Biology, Neuro-oncology, Glioblastoma Growth +11

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

T. Annie T. Fong, Laura K. Shawver, Li Sun et al. · PubMed · 1999 · 1K citations

Novel Synthetic Compound, Chemoprevention Strategy, Pathology +20

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

Alexander Laird, Peter Vajkoczy, Laura K. Shawver et al. · PubMed · 2000 · 497 citations

Pathology, Cancer Biology, Tumor Biology +23

Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis

Daniel J. Anderson, Ronan Le Moigne, Stevan Djakovic et al. · Cancer Cell · 2015 · 392 citations · Full text

Protein Function, Medicine, Natural Sciences +13

Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases

Li Sun, Ngoc Quang Tran, Congxin Liang et al. · Journal of Medicinal Chemistry · 1999 · 271 citations · Full text

Tyrosine Kinase, Immunology, Pharmacotherapy +16